The Beauty Health shares surge 18.40% intraday after exceeding Q4 sales and EBITDA forecasts and shifting strategy to boost equipment utilization and consumables revenue.

The Beauty Health surged 18.40% intraday trading, driven by Q4 2025 results exceeding expectations with $82.4 million in sales (vs. $77.8M estimated) and adjusted EBITDA of $15 million (vs. $8.26M estimated), alongside a 67.4% adjusted gross margin. The company also announced a strategic shift to boost equipment utilization through optimized sales and marketing, driving 1.7% growth in consumables revenue to $57.7 million and a 2026 guidance of $285–$305 million net sales and $35–$45 million adjusted EBITDA, reflecting sustained profitability.